Skip to content

Study · Non-randomized trial · 1993

3 results

[The clinico-epidemiological efficacy of thymogen in acute respiratory viral infections in a military collective].

Furgal SM, Degtiarev AA, Seryĭ SV, Khavinson VKh

Voenno-meditsinskii zhurnal1 Feb 1993

PMID8498021 (opens in a new tab)PepBankPUB-08498021
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In a military training unit, intranasal and subcutaneous timogen reduced acute respiratory infection morbidity.

    In plain wordsIn a military training unit, timogen reduced the rate of acute respiratory infections.

    Peptide
    Thymogen (oglufanide)
    Outcome
    DecreaseARI morbidity rate
    Study

    n: not reported in source

    Outcome group
    Infection and antimicrobial activity · Respiratory
    Studied dose
    Dose not stated · intranasal and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The high clinico-epidemiological efficiency of timogen was proved in intranasal and subcutaneous administration that had led to a considerable reduction of morbidity rate, gravity and duration of ARI.
    1 context sentence
    Summary · context
    This study gathers the results of epidemiological examination in training military unit, making evaluation of prophylactic efficiency of timogen, i.e. synthetic peptide of thymus for flu and other acute respiratory infections (ARI).
  2. 02HumanNon-randomized trialEfficacy outcome

    In a military training unit, intranasal and subcutaneous timogen reduced acute respiratory infection severity.

    In plain wordsIn a military training unit, timogen reduced the severity of acute respiratory infections.

    Peptide
    Thymogen (oglufanide)
    Outcome
    DecreaseARI severity
    Study

    n: not reported in source

    Outcome group
    Infection and antimicrobial activity · Respiratory
    Studied dose
    Dose not stated · intranasal and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The high clinico-epidemiological efficiency of timogen was proved in intranasal and subcutaneous administration that had led to a considerable reduction of morbidity rate, gravity and duration of ARI.
    1 context sentence
    Summary · context
    This study gathers the results of epidemiological examination in training military unit, making evaluation of prophylactic efficiency of timogen, i.e. synthetic peptide of thymus for flu and other acute respiratory infections (ARI).
  3. 03HumanNon-randomized trialEfficacy outcome

    In a military training unit, intranasal and subcutaneous timogen reduced acute respiratory infection duration.

    In plain wordsIn a military training unit, timogen reduced the duration of acute respiratory infections.

    Peptide
    Thymogen (oglufanide)
    Outcome
    DecreaseARI duration
    Study

    n: not reported in source

    Outcome group
    Infection and antimicrobial activity · Respiratory
    Studied dose
    Dose not stated · intranasal and subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The high clinico-epidemiological efficiency of timogen was proved in intranasal and subcutaneous administration that had led to a considerable reduction of morbidity rate, gravity and duration of ARI.
    1 context sentence
    Summary · context
    This study gathers the results of epidemiological examination in training military unit, making evaluation of prophylactic efficiency of timogen, i.e. synthetic peptide of thymus for flu and other acute respiratory infections (ARI).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.